[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-001", "question": "A 58-year-old man with a history of hypertrophic cardiomyopathy presents with recurrent syncope. Genetic testing reveals a mutation in the MYH7 gene. Echocardiography shows asymmetric septal hypertrophy with a left ventricular outflow tract gradient of 80 mmHg at rest. Despite optimal medical therapy with beta-blockers, he continues to experience symptoms. What is the most appropriate next step in management?", "options": ["Alcohol septal ablation", "Surgical myectomy", "Implantation of a dual-chamber pacemaker", "Addition of disopyramide", "Cardiac resynchronization therapy"], "answer": "D", "answer_index": 3, "explanation": "Addition of disopyramide is the most appropriate next step as it is recommended for symptomatic hypertrophic cardiomyopathy with obstruction refractory to beta-blockers, acting as a negative inotrope to reduce the gradient. Alcohol septal ablation and surgical myectomy are invasive options considered only after failure of medical therapy including disopyramide. Pacemaker implantation and cardiac resynchronization therapy are not first-line for outflow tract obstruction in this context.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with symptomatic obstructive hypertrophic cardiomyopathy (HCM). He has severe symptoms (recurrent syncope) and a significant resting LVOT gradient (80 mmHg) despite therapy with beta-blockers.\n\nThe management of symptomatic obstructive HCM generally follows a stepwise approach:\n1.  First-line pharmacologic therapy: Monotherapy with non-vasodilating beta-blockers (titrated to maximal tolerated dose) or calcium channel blockers (verapamil or diltiazem) if beta-blockers are not tolerated or ineffective.\n2.  Second-line pharmacologic therapy: If symptoms persist on monotherapy, the addition of disopyramide is recommended. Disopyramide is a Class Ia antiarrhythmic with potent negative inotropic properties that reduce the LVOT gradient and improve symptoms. It is usually administered in combination with a beta-blocker (to prevent rapid AV conduction possibly induced by disopyradmide's vagolytic effects).\n3.  Septal Reduction Therapy (SRT): Surgical myectomy or alcohol septal ablation is indicated for patients with severe, drug-refractory symptoms (NYHA Class III-IV or recurrent syncope) despite optimal medical therapy (which typically implies a trial of combination therapy including disopyramide, unless contraindicated or not tolerated) and an LVOT gradient $\\ge$ 50 mmHg.\n\nIn this scenario, the patient is currently only on beta-blockers (\"optimal medical therapy with beta-blockers\" implies the beta-blocker dose is optimized, not that all medical options are exhausted). There is no mention of disopyramide use or contraindications (e.g., glaucoma, urinary retention, prolonged QT). Therefore, the addition of disopyramide is the most appropriate next step to attempt medical control of the gradient and symptoms before proceeding to invasive open-heart surgery (myectomy).\n\nWhile surgical myectomy (Option B) is the gold standard for SRT and would be the choice if medical therapy fails, the patient has not yet failed combination pharmacotherapy. Pacemakers (Option C) and alcohol septal ablation (Option A) are generally considered alternatives when myectomy is contraindicated or based on specific patient preferences/anatomies, but they are not the immediate next step here. CRT (Option E) is indicated for heart failure with reduced ejection fraction and wide QRS, not typical obstructive HCM.\n\nThe answer is (D)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-002", "question": "A 4-year-old boy with a history of recurrent urinary tract infections is found to have vesicoureteral reflux on voiding cystourethrogram. Renal ultrasound shows mild hydronephrosis. Despite prophylactic antibiotics, he develops breakthrough infections. Genetic evaluation reveals a mutation in the PAX2 gene. What is the most likely associated syndrome?", "options": ["Denys-Drash syndrome", "Renal coloboma syndrome", "Branchio-oto-renal syndrome", "Alport syndrome", "Frasier syndrome"], "answer": "B", "answer_index": 1, "explanation": "Renal coloboma syndrome is associated with PAX2 mutations, characterized by renal hypoplasia, vesicoureteral reflux, and optic nerve colobomas. Denys-Drash and Frasier syndromes involve WT1 mutations, while Alport syndrome relates to collagen IV defects. Branchio-oto-renal syndrome is linked to EYA1 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Based on the genetic finding provided in the clinical vignette, here is the breakdown of the options:\n\n*   A. Denys-Drash syndrome: This is caused by mutations in the WT1 gene. It is characterized by Wilms tumor, diffuse mesangial sclerosis (early-onset nephrotic syndrome), and male pseudohermaphroditism.\n*   B. Renal coloboma syndrome (Papillorenal syndrome): This syndrome is caused by mutations in the PAX2 gene. *PAX2* is a transcription factor critical for the development of the urogenital tract and the eyes. Clinical features include renal hypoplasia/dysplasia, vesicoureteral reflux (VUR), and optic nerve colobomas (\"morning glory\" disc anomaly). The renal presentation in the vignette (VUR, hydronephrosis) is consistent with this diagnosis.\n*   C. Branchio-oto-renal syndrome: This is primarily caused by mutations in the EYA1, SIX1, or SIX5 genes. It involves branchial cleft fistulas/cysts, ear malformations/hearing loss, and renal anomalies.\n*   D. Alport syndrome: This is caused by mutations in type IV collagen genes (COL4A3, COL4A4, COL4A5). It presents with hematuria, proteinuria, progressive renal failure, sensorineural hearing loss, and ocular defects like anterior lenticonus.\n*   E. Frasier syndrome: This corresponds to specific splice site mutations in the WT1 gene. It is characterized by focal segmental glomerulosclerosis (FSGS) and complete gonadal dysgenesis (XY females).\n\nTherefore, the mutation in the *PAX2* gene identifies the condition as Renal coloboma syndrome.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-003", "question": "In the emergency department, a 32-year-old woman presents with acute chest pain and dyspnea following a long-haul flight. CT pulmonary angiography confirms a segmental pulmonary embolism. She has a history of oral contraceptive use and a positive family history for thrombophilia. Laboratory testing shows elevated factor VIII levels. What is the most appropriate initial anticoagulant therapy?", "options": ["Low-molecular-weight heparin followed by warfarin", "Direct oral anticoagulant such as rivaroxaban", "Unfractionated heparin with thrombolysis", "Fondaparinux monotherapy", "Aspirin and clopidogrel combination"], "answer": "B", "answer_index": 1, "explanation": "Direct oral anticoagulants like rivaroxaban are preferred for initial treatment of pulmonary embolism in non-pregnant patients without severe renal impairment or active cancer. Low-molecular-weight heparin followed by warfarin is an alternative but less convenient. Thrombolysis is reserved for hemodynamically unstable cases, and antiplatelet therapy is insufficient for venous thromboembolism.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This clinical scenario describes a patient with a hemodynamically stable acute pulmonary embolism (segmental PE), provoked by risk factors such as oral contraceptive use, long-haul travel, and a background of elevated factor VIII.\n\n1.  Assessment of Stability: The patient has a segmental PE and there is no mention of hemodynamic instability (e.g., hypotension, shock). Therefore, thrombolysis (Option C) is not indicated, as it carries a significant risk of bleeding and is reserved for high-risk (unstable) patients.\n2.  Choice of Anticoagulant: The mainstay of treatment for acute PE is anticoagulation. Current clinical practice guidelines (such as those from the American College of Chest Physicians [CHEST] and the European Society of Cardiology [ESC]) recommend Direct Oral Anticoagulants (DOACs) – including rivaroxaban, apixaban, edoxaban, and dabigatran – over Vitamin K Antagonists (warfarin) for the vast majority of patients with VTE who do not have cancer.\n3.  Rationale for DOACs: DOACs have a favorable safety profile (particularly lower rates of intracranial hemorrhage compared to warfarin), a rapid onset of action, and do not require routine monitoring (INR). Rivaroxaban (Option B) and apixaban can be initiated as monotherapy with an oral loading dose, removing the need for initial parenteral anticoagulation (like LMWH).\n4.  Other Options:\n    *   Option A: LMWH bridging to warfarin is a valid traditional treatment but is generally less preferred now due to the complexity of bridging, need for injections, and INR monitoring, unless there are contraindications to DOACs (e.g., severe renal impairment, antiphospholipid syndrome). Elevated Factor VIII is not a contraindication to DOACs.\n    *   Option D: Fondaparinux is used for initial parenteral anticoagulation but is not standard monotherapy for the full course of treatment; it is usually followed by VKA or a DOAC.\n    *   Option E: Antiplatelet agents like aspirin and clopidogrel are insufficient for treating acute venous thromboembolism.\n\nTherefore, the most appropriate initial anticoagulant therapy among the choices provided is a direct oral anticoagulant.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-004", "question": "A 45-year-old woman presents with symmetric polyarthritis, morning stiffness, and a rash on her trunk. Laboratory tests show positive anti-citrullinated protein antibodies and elevated inflammatory markers. Despite methotrexate therapy, her disease progresses. Genetic testing reveals a mutation in the NLRP3 gene. What is the most likely diagnosis?", "options": ["Rheumatoid arthritis", "Cryopyrin-associated periodic syndrome", "Adult-onset Still's disease", "Behçet's disease", "Systemic lupus erythematosus"], "answer": "B", "answer_index": 1, "explanation": "Cryopyrin-associated periodic syndrome involves NLRP3 mutations, presenting with arthritis, rash, and autoinflammatory features that may mimic rheumatoid arthritis but respond poorly to standard DMARDs. Rheumatoid arthritis typically lacks this genetic mutation and responds to methotrexate. Adult-onset Still's disease and others do not feature NLRP3 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient presents with polyarthritis and a rash, initially treated for Rheumatoid Arthritis (RA) given the positive anti-citrullinated protein antibodies (ACPA). However, the disease is refractory to methotrexate (a standard RA therapy), and genetic testing reveals a mutation in the NLRP3 gene.\n\nPoints to consider:\n1.  NLRP3 Gene: Mutations in the *NLRP3* gene (specifically gain-of-function mutations) are the cause of Cryopyrin-Associated Periodic Syndromes (CAPS). These are autoinflammatory disorders.\n2.  Clinical Presentation: CAPS encompasses a spectrum of disorders (Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, and Neonatal-Onset Multisystem Inflammatory Disease). Common features include recurrent fever, urticaria-like rash (often overlapping with the trunk rash described), and arthralgia or arthritis.\n3.  Refractory Disease: Patients with CAPS do not typically respond to T-cell/B-cell targeted therapies like methotrexate used in RA. They respond to IL-1 inhibitors (e.g., anakinra, canakinumab). The progression despite methotrexate supports a non-RA diagnosis.\n4.  The Distractor: The positive ACPA is highly specific for RA, making this a challenging clinical vignette. However, in the context of a board exam question where a definitive pathogenic genetic mutation is provided (*NLRP3*), the genetic finding defines the diagnosis. While rare, ACPA positivity can occur in other inflammatory states or this could represent a case of CAPS mimicking RA (or co-occurrence), but the *cause* identified by the mutation makes CAPS the intended answer.\n\nTherefore, the identification of the *NLRP3* mutation confirms the diagnosis of a cryopyrin-associated periodic syndrome.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-005", "question": "A 28-year-old man with type 1 diabetes mellitus presents with recurrent hypoglycemia despite insulin dose adjustments. Continuous glucose monitoring shows nocturnal hypoglycemia. Laboratory evaluation reveals elevated proinsulin levels and a low C-peptide. What is the most likely underlying mechanism?", "options": ["Insulinoma", "Factitious hypoglycemia from exogenous insulin", "Adrenal insufficiency", "Autoimmune hypoglycemia", "Nesidioblastosis"], "answer": "B", "answer_index": 1, "explanation": "Factitious hypoglycemia from exogenous insulin is indicated by low C-peptide and elevated proinsulin due to suppressed endogenous insulin production. Insulinoma would show high C-peptide and proinsulin. Adrenal insufficiency typically causes hyperglycemia, and autoimmune hypoglycemia involves insulin antibodies with variable C-peptide.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "This patient with Type 1 Diabetes Mellitus (T1DM) presents with hypoglycemia, low C-peptide, and elevated proinsulin. Here is the breakdown of the options based on these findings:\n\n1.  Low C-peptide: C-peptide is a byproduct of endogenous insulin production. In T1DM, beta-cell function is lost, so C-peptide is typically low or undetectable. An insulin-secreting tumor (Insulinoma) or Nesidioblastosis would produce endogenous insulin, leading to high C-peptide levels. Therefore, Options A (Insulinoma) and E (Nesidioblastosis) are incorrect.\n\n2.  Elevated Proinsulin: Proinsulin is the precursor to insulin.\n    *   Factitious Hypoglycemia (Option B): Patients injecting exogenous insulin will have high serum insulin levels and low C-peptide (due to suppression of endogenous production). However, modern pharmaceutical insulin preparations are purified and do not contain proinsulin. Consequently, proinsulin levels should be low or suppressed. The finding of *elevated* proinsulin argues strongly against factitious insulin use.\n    *   Adrenal Insufficiency (Option C): While adrenal insufficiency can cause hypoglycemia in T1DM due to the loss of counter-regulatory cortisol, it does not explain the elevation of proinsulin levels.\n\n3.  Autoimmune Hypoglycemia (Option D): Patients with T1DM treated with exogenous insulin often develop anti-insulin antibodies. These antibodies can bind to the injected insulin and release it unpredictably, causing hypoglycemia. Importantly, these antibodies can also bind to proinsulin (which shares structural similarity with insulin) or interfere with proinsulin assays. This binding extends the half-life of proinsulin or causes assay artifacts, leading to elevated measured proinsulin levels. Since the antibodies do not bind C-peptide (which is structurally distinct), C-peptide levels remain low, accurately reflecting the patient's lack of endogenous insulin secretion.\n\nThe combination of High Proinsulin and Low C-peptide in a T1DM patient is the hallmark laboratory profile for hypoglycemia mediated by insulin antibodies.\n\nThe answer is (D)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-006", "question": "A 65-year-old man with ischemic cardiomyopathy and an ejection fraction of 25% develops sustained ventricular tachycardia. He is hemodynamically stable. Electrophysiology study identifies a reentrant circuit in the infarct border zone. Despite amiodarone therapy, episodes recur. What is the most appropriate next intervention?", "options": ["Catheter ablation", "Implantable cardioverter-defibrillator upgrade to biventricular", "Addition of mexiletine", "Stellate ganglionectomy", "Cardiac sympathetic denervation"], "answer": "A", "answer_index": 0, "explanation": "Catheter ablation is the most appropriate for recurrent ventricular tachycardia in ischemic cardiomyopathy refractory to antiarrhythmic drugs, targeting the reentrant circuit. ICD upgrade addresses heart failure but not arrhythmia substrate directly. Mexiletine addition is less effective for scar-related VT, and surgical options like ganglionectomy are reserved for refractory cases.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Based on current clinical guidelines (e.g., AHA/ACC/HRS) and evidence from trials such as the VANISH trial, catheter ablation is the recommended intervention for patients with ischemic cardiomyopathy and recurrent sustained monomorphic ventricular tachycardia (VT) despite antiarrhythmic drug therapy (specifically amiodarone).\n\nThe VANISH trial demonstrated that in patients with ischemic cardiomyopathy who had VT while taking antiarrhythmic drugs, catheter ablation resulted in a significantly lower rate of the composite outcome of death, ventricular tachycardia storm, or appropriate ICD shock compared to escalated antiarrhythmic drug therapy (which would include adding mexiletine).\n\nBiventricular pacing (CRT) is indicated for heart failure management (depending on QRS morphology and duration) but does not directly treat the VT substrate. Cardiac sympathetic denervation (stellate ganglionectomy) is typically reserved for cases of refractory VT storm where medications and ablation have failed.\n\nThe answer is (A)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-007", "question": "An 8-year-old girl with short stature and failure to thrive undergoes evaluation. Bone age is delayed, and laboratory tests show low IGF-1 with normal growth hormone stimulation. Genetic testing reveals a mutation in the IGF1R gene. What is the most appropriate management strategy?", "options": ["Recombinant growth hormone therapy", "IGF-1 replacement therapy", "Nutritional supplementation", "Thyroid hormone replacement", "Corticosteroid therapy"], "answer": "B", "answer_index": 1, "explanation": "IGF-1 replacement therapy is indicated for IGF1R mutations causing primary IGF-1 deficiency resistant to growth hormone. Recombinant growth hormone would be ineffective due to receptor defect. Nutritional or hormonal supplements like thyroid or corticosteroids do not address the underlying IGF-1 resistance.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient is an 8-year-old girl with short stature, failure to thrive, and a confirmed genetic mutation in the IGF1R (Insulin-like Growth Factor 1 Receptor) gene. This condition represents a state of IGF-1 resistance (or insensitivity).\n\n1.  Pathophysiology: The defect lies in the IGF-1 receptor. Tissues are less sensitive to the effects of IGF-1. Although classical descriptions of hormone resistance usually involve elevated levels of the ligand (IGF-1) due to lack of feedback inhibition, patients with *IGF1R* mutations can present with variable IGF-1 levels (high, normal, or even low, particularly if failure to thrive and malnutrition are significant features, as they often are in this syndrome).\n2.  Management Strategy:\n    *   Recombinant growth hormone (rhGH) (Option A): This is the generally accepted and most appropriate management strategy for patients with *IGF1R* mutations. Since the Growth Hormone Receptor (GHR) is intact, administration of rhGH effectively stimulates the liver to produce higher levels of IGF-1 and IGFBP3. The resulting supraphysiologic levels of circulating and local IGF-1 help to overcome the partial resistance of the IGF-1 receptors. Clinical studies indicate that these patients respond well to rhGH therapy, often creating catch-up growth.\n    *   IGF-1 replacement therapy (Option B): Mecasermin (rhIGF-1) is indicated for Severe Primary IGF-1 Deficiency (SPIGFD). This diagnosis requires low IGF-1, normal/high GH, and typically a defect in the GH receptor (Laron syndrome), GH signal transduction (STAT5B), or the *IGF1* gene itself. It is generally not indicated for *IGF1R* (receptor) mutations because the defect is in the receiver of the signal; furthermore, rhGH is effective and preserves the physiological regulation of the GH-IGF axis better than exogenous IGF-1.\n    *   Nutritional supplementation (Option C): While nutritional support is necessary for failure to thrive, it is an adjunct. The specific pharmacological intervention for the genetic short stature described is GH therapy.\n    *   Thyroid hormone/Corticosteroids (Options D/E): There is no evidence of hypothyroidism, and corticosteroids would inhibit growth.\n\nDespite the \"low IGF-1\" finding in the vignette (which resembles the lab profile of Laron syndrome or nutritional deficiency), the specific genetic diagnosis of an *IGF1R* mutation dictates the treatment. Since the GH receptor is functional, the axis can be driven by exogenous GH to overcome the downstream partial resistance.\n\nThe answer is A\n\nThe answer is (A)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-008", "question": "In the emergency department, a 50-year-old man presents with severe abdominal pain and vomiting. CT scan shows acute pancreatitis with necrosis. He develops hypotension and acute kidney injury. Serum triglycerides are 1200 mg/dL. What is the most appropriate initial management for the hypertriglyceridemia?", "options": ["Plasmapheresis", "Insulin infusion", "Fibrates", "Niacin", "Statins"], "answer": "B", "answer_index": 1, "explanation": "Insulin infusion effectively lowers triglycerides in hypertriglyceridemic pancreatitis by enhancing lipoprotein lipase activity. Plasmapheresis is reserved for severe cases not responding to insulin. Fibrates, niacin, and statins are long-term therapies not suitable for acute management.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Here is the step-by-step reasoning for the correct answer:\n\n1.  Diagnosis: The patient presents with acute pancreatitis confirmed by CT imaging (necrosis) and significantly elevated serum triglycerides (1200 mg/dL). A triglyceride level >1000 mg/dL is a well-established cause of acute pancreatitis.\n2.  Severity Assessment: The patient has signs of severe acute pancreatitis complicated by organ failure, evidenced by hypotension (shock) and acute kidney injury (AKI).\n3.  Management Goal: In hypertriglyceridemia-induced pancreatitis (HTGP), the primary specific goal is to rapidly lower serum triglyceride levels (ideally to <500 mg/dL) to halt the inflammatory cascade and prevent further pancreatic necrosis and systemic complications.\n4.  Evaluating Options:\n    *   Options C (Fibrates), D (Niacin), and E (Statins): These are oral lipid-lowering agents used for long-term management. They have a slow onset of action and are ineffective in the acute setting to rapidly lower triglycerides. Additionally, oral administration contributes to gut stimulation which is generally avoided in acute pancreatitis with vomiting.\n    *   Option B (Insulin infusion): Intravenous insulin (often with dextrose) activates lipoprotein lipase (LPL), which breaks down triglycerides. It is an effective treatment and is often used for patients who are hemodynamically stable or where apheresis is unavailable. However, the reduction in triglycerides is slower compared to apheresis.\n    *   Option A (Plasmapheresis): Therapeutic plasma exchange (plasmapheresis) physically removes triglycerides from the blood. It is the most rapid method, capable of reducing triglyceride levels by 50-80% within a few hours. Clinical guidelines (such as those referenced in UpToDate and by the American Society for Apheresis) suggest plasmapheresis for patients with HTGP who present with \"worrying features,\" specifically hypocalcemia, lactic acidosis, or signs of worsening organ dysfunction (like the hypotension and AKI seen in this patient).\n\n5.  Conclusion: Given the patient's critical condition with organ failure (hypotension, AKI) and necrosis, the most appropriate and aggressive initial management to rapidly reverse the metabolic precipitant is plasmapheresis.\n\nThe answer is (A)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-009", "question": "A 35-year-old woman with seropositive rheumatoid arthritis on infliximab develops fever, weight loss, and lymphadenopathy. Biopsy shows non-caseating granulomas. Serum angiotensin-converting enzyme is elevated. What is the most likely diagnosis?", "options": ["Tuberculosis reactivation", "Infliximab-induced sarcoidosis", "Lymphoma", "Fungal infection", "Amyloidosis"], "answer": "B", "answer_index": 1, "explanation": "Infliximab-induced sarcoidosis is a rare complication of TNF inhibitors, presenting with granulomatous inflammation mimicking sarcoidosis. Tuberculosis would show caseating granulomas and positive cultures. Lymphoma or infections are differentials but less likely without specific evidence.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient has rheumatoid arthritis and is being treated with infliximab (a TNF-alpha inhibitor). She presents with classical signs of sarcoidosis: fever, weight loss, lymphadenopathy, non-caseating granulomas on biopsy, and elevated serum angiotensin-converting enzyme (ACE) levels.\n\nWhile anti-TNF agents are used to treat sarcoidosis, they can paradoxically induce sarcoidosis-like granulomatosis (a known non-infectious paradoxical adverse effect).\n\nHere is a breakdown of why the other options are less likely:\n*   Tuberculosis reactivation (A): While anti-TNF therapy increases the risk of TB, tuberculous granulomas are typically caseating (necrotizing). The finding of non-caseating granulomas and elevated ACE is more specific to sarcoidosis in obtaining a differential diagnosis.\n*   Lymphoma (C): While there is a concern for malignancy with immunomodulators, the biopsy would demonstrate malignant proliferation of lymphocytes, not granulomas.\n*   Fungal infection (D): Fungal infections can cause granulomas (often caseating), but the combination of non-caseating granulomas and elevated ACE in the context of TNF-inhibitor therapy strongly points to the specific syndrome of drug-induced sarcoidosis.\n*   Amyloidosis (E): Secondary amyloidosis (AA type) can occur in chronic inflammatory states like RA, but the biopsy would show amorphous material that demonstrates apple-green birefringence under polarized light with Congo red staining, not proliferation of granulomas.\n\nThe answer is (B)"}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-010", "question": "A 42-year-old woman with acromegaly undergoes transsphenoidal surgery, but IGF-1 levels remain elevated postoperatively. She declines further surgery. What is the most appropriate pharmacologic therapy?", "options": ["Cabergoline", "Pegvisomant", "Octreotide", "Pasireotide", "Bromocriptine"], "answer": "B", "answer_index": 1, "explanation": "Pegvisomant, a growth hormone receptor antagonist, is the most effective for normalizing IGF-1 in acromegaly resistant to surgery and somatostatin analogs. Octreotide and pasireotide are somatostatin analogs that may not suffice post-surgery. Dopamine agonists like cabergoline or bromocriptine are less potent for pure GH-secreting adenomas.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Based on clinical guidelines (such as those from the Endocrine Society), the first-line medical therapy for patients with acromegaly who have persistent disease after surgery is a somatostatin receptor ligand (SRL).\n\n*   Octreotide (Option C) and lanreotide are first-generation somatostatin analogs and are the standard initial choice for pharmacologic therapy in this setting.\n*   Cabergoline (Option A) and Bromocriptine (Option E) are dopamine agonists. They are generally less effective than somatostatin analogs and are typically reserved for patients with only mild IGF-1 elevations or as adjunctive therapy, particularly if there is co-secretion of prolactin.\n*   Pegvisomant (Option B) is a growth hormone receptor antagonist. While highly effective, it is typically used as a second-line treatment for patients who do not respond adequately to somatostatin analogs.\n*   Pasireotide (Option D) is a second-generation somatostatin analog generally reserved for patients resistant to first-generation agents (octreotide/lanreotide).\n\nTherefore, Octreotide is the most appropriate initial pharmacologic therapy.\n\nThe answer is (C)"}]